| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Catenin Expression in Prostate Cancer: Correlation with Patient Survival1
Department of Surgery, Royal Free Hospital, London NW3 2QC, United Kingdom [P. J. M. R., A. V. K.]; Department of Surgery [A. J. K.] and Cell Adhesion Laboratory. Department of Histopathology [M. P.], Royal Postgraduate Medical School, Du Cane Road, London W12 0NN, United Kingdom; and Department of Cell Biology, Faculty of Medicine, Kyoto University, Kyoto 606, Japan [A. N.]
E-cadherin maintains the normal differentiated phenotype in epithelial cells; this function is partly mediated by 
-catenin, which links E-cadherin to the cell cytoskeleton. Dysfunction of E-cadherin in vitro and in vivo is associated with an invasive phenotype. However, the role of -catenin is largely undetermined. We analyzed the expression of E-cadherin and -catenin in prostate cancer to assess the relationship of abnormal expression to stage, grade and survival. E-cadherin expression was evaluated in 99 prostate cancers. In 79 of those specimens, -catenin was also assessed. In benign prostatic epithelium, both E-cadherin and -catenin were expressed uniformly at the cell membrane. Abnormal E-cadherin expression was found in 56% of cancer specimens, whereas -catenin expression was abnormal in 42%. Abnormal expression of each molecule was significantly correlated with Gleason score (P < 0.0001) and the ratio of resection chippings infiltrated by tumor (P < 0.0001). E-cadherin expression was also associated with the extent of disease on the initial bone scan (P = 0.017). Univariate analysis showed significantly lower survival rate for patients with abnormal E-cadherin (P = 0.0003) or -catenin expression (P = 0.031). Multivariate regression analysis showed that the prognostic value of E-cadherin was independent of tumor grade but not of metastasis. These results suggest that perturbation of cell-cell adhesion is involved in the progression of prostate cancer and that analysis of E-cadherin expression may be clinically useful.
1 A. J. K. was supported by a scholarship in Surgical Oncology from the Greek State Scholarships Foundation.
2 To whom requests for reprints should be addressed. Phone: 44-181-383-2432; Fax: 44-181-740-7417; E-mail: m.pignatelli@rpms.ac.uk.
Received 1/23/97. Accepted 5/29/97.
This article has been cited by other articles:
|
|
 |
|
  J. Zabaleta, L. J. Su, H.-Y. Lin, R. A. Sierra, M. C. Hall, A. O. Sartor, P. E. Clark, J. J. Hu, and A. C. Ochoa Cytokine genetic polymorphisms and prostate cancer aggressiveness Carcinogenesis, August 1, 2009; 30(8): 1358 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhou, B. Yan, X. Hu, X.-B. Li, J. Zhang, and J. Fang Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin Mol. Cancer Ther., June 1, 2009; 8(6): 1684 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Inge, S. A. Rajasekaran, D. Wolle, S. P. Barwe, S. Ryazantsev, C. M. Ewing, W. B. Isaacs, and A. K. Rajasekaran {alpha}-Catenin overrides Src-dependent activation of {beta}-catenin oncogenic signaling Mol. Cancer Ther., June 1, 2008; 7(6): 1386 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7003 - 7011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Buijs, C. A. Rentsch, G. van der Horst, P. G.M. van Overveld, A. Wetterwald, R. Schwaninger, N. V. Henriquez, P. ten Dijke, F. Borovecki, R. Markwalder, et al. BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo Am. J. Pathol., September 1, 2007; 171(3): 1047 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Verras and Z. Sun {beta}-Catenin Is Involved in Insulin-Like Growth Factor 1-Mediated Transactivation of the Androgen Receptor Mol. Endocrinol., February 1, 2005; 19(2): 391 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Faleiro-Rodrigues, I. Macedo-Pinto, D. Pereira, and C. S. Lopes Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas Ann. Onc., October 1, 2004; 15(10): 1535 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuniyasu, R. Ukai, D. Johnston, P. Troncoso, I. J. Fidler, and C. A. Pettaway The Relative mRNA Expression Levels of Matrix Metalloproteinase to E-Cadherin in Prostate Biopsy Specimens Distinguishes Organ-confined from Advanced Prostate Cancer at Radical Prostatectomy Clin. Cancer Res., June 1, 2003; 9(6): 2185 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Khan and A. W. Partin Management of High-Risk Populations with Locally Advanced Prostate Cancer Oncologist, June 1, 2003; 8(3): 259 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rios-Doria, K. C. Day, R. Kuefer, M. G. Rashid, A. M. Chinnaiyan, M. A. Rubin, and M. L. Day The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells J. Biol. Chem., January 3, 2003; 278(2): 1372 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Campbell and M Pignatelli Molecular histology in the study of solid tumours Mol. Pathol., April 1, 2002; 55(2): 80 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yang, X. Li, M. Sharma, C. Y. Sasaki, D. L. Longo, B. Lim, and Z. Sun Linking beta -Catenin to Androgen-signaling Pathway J. Biol. Chem., March 22, 2002; 277(13): 11336 - 11344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Rashid, M. G. Sanda, C. J. Vallorosi, J. Rios-Doria, M. A. Rubin, and M. L. Day Posttranslational Truncation and Inactivation of Human E-Cadherin Distinguishes Prostate Cancer from Matched Normal Prostate Cancer Res., January 1, 2001; 61(2): 489 - 492. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Böhm, L. Niskanen, K. Kiraly, J. Kellokoski, M. Eskelinen, S. Hollmen, E. Alhava, and V.-M. Kosma Expression and Prognostic Value of {{alpha}}-, {beta}-, and {{gamma}}-Catenins in Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4806 - 4811. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kase, K. Sugio, K. Yamazaki, T. Okamoto, T. Yano, and K. Sugimachi Expression of E-cadherin and {beta}-Catenin in Human Non-Small Cell Lung Cancer and the Clinical Significance Clin. Cancer Res., December 1, 2000; 6(12): 4789 - 4796. [Abstract] [Full Text]
|
|
|
|
|
|
E. A. Sheta, M. A. Harding, M. R. Conaway, and D. Theodorescu Focal Adhesion Kinase, Rap1, and Transcriptional Induction of Vascular Endothelial Growth Factor J Natl Cancer Inst, July 5, 2000; 92(13): 1065 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tomita, A. van Bokhoven, G. J. L. H. van Leenders, E. T. G. Ruijter, C. F. J. Jansen, M. J. G. Bussemakers, and J. A. Schalken Cadherin Switching in Human Prostate Cancer Progression Cancer Res., July 1, 2000; 60(13): 3650 - 3654. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kuniyasu, P. Troncoso, D. Johnston, C. D. Bucana, E. Tahara, I. J. Fidler, and C. A. Pettaway Relative Expression of Type IV Collagenase, E-cadherin, and Vascular Endothelial Growth Factor/Vascular Permeability Factor in Prostatectomy Specimens Distinguishes Organ-confined from Pathologically Advanced Prostate Cancers Clin. Cancer Res., June 1, 2000; 6(6): 2295 - 2308. [Abstract] [Full Text]
|
|
|
|
|
|
J. Luo, D. M. Lubaroff, and M. J. C. Hendrix Suppression of Prostate Cancer Invasive Potential and Matrix Metalloproteinase Activity by E-Cadherin Transfection Cancer Res., August 1, 1999; 59(15): 3552 - 3556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Rondinelli and J. V. Tricoli CLAR1, a Novel Gene That Exhibits Enhanced Expression in Advanced Human Prostate Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1595 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pötter, C. Bergwitz, and G. Brabant The Cadherin-Catenin System: Implications for Growth and Differentiation of Endocrine Tissues Endocr. Rev., April 1, 1999; 20(2): 207 - 239. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]
|
|
|
|
|
|
N. N. Nupponen, L. Kakkola, P. Koivisto, and T. Visakorpi Genetic Alterations in Hormone-Refractory Recurrent Prostate Carcinomas Am. J. Pathol., July 1, 1998; 153(1): 141 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Spiryda and D. Colman Suppression of tumorigenicity in an aggressive cervical carcinoma induced by protein zero, a nervous system IgCAM J. Cell Sci., January 11, 1998; 111(22): 3253 - 3260. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
